NEW! Investment Companies Centre

BTG cheered by prostate cancer success

Related Companies

Related Indices

Related Sectors

News for Spread Betters

PreviousPrevious
NextNext

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here. Advertisement

Date: Tuesday 22 Jul 2008

LONDON (ShareCast) - BTG regained upward momentum today on news that abiraterone, a drug it licensed to Cougar Biotechnology, can successfully treat aggressive, chemotherapy-resistant prostate cancer.

A new study in the Journal of Clinical Oncology revealed that abiraterone, or CB7630, caused “significant” tumour shrinkage and reduction in prostate specific antigen levels in 70-80% of men with the disease.

The life sciences company, which last week said trading is in line with expectations, bought the drug from the Institute of Cancer Research and funded its early stage development.

“We are delighted that abiraterone continues to show excellent potential as a new treatment for these resistant forms of prostate cancer, which represent a significant unmet need,” said BTG boss Louise Makin.

BTG will receive milestone payments and royalties on sales of CB7630 if it is successfully developed and approved for sale.

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).